Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Favorable efficacy and safety outcomes were reported following treatment with TULSA, including an improvement in urinary quality of life with median IPSS improving 60% from 17 which is moderate LUTS or lower urinary tract symptoms, to six which is mild LUTS |
| Very well deserved |
| While our team has done a really good job with all three, the penetration we have achieved into the latter really stands out as truly exceptional at the stage we're in today |
| As a result, we believe we remain well positioned to complete enrollment of the CAPTAIN Study this year which would allow publication of preliminary data in the first half of 2025, followed by the full one-year primary safety outcomes in early 2026 and three-year primary efficacy outcomes in early 2028 |
| And finally, we're delighted with the progress of patient recruitment in the Level 1 clinical trial that compares the TULSA procedure with radical prostatectomy |
| As our treatment and outcome database grows, the knowledge of the AI will continue to increase and as a result, Contouring Assistant proposed treatment design will continue to improve, thereby enhancing clinical outcomes while also reducing treatment times |
| I'm pleased to report that we successfully executed against key strategic priorities in 2023 |
| Also I mean, just to see, I think the Mayo was a very good example where they started, very conservative start at the Florida site, and then it went on to the Rochester site, which is doing very well |
| But I do think that coming into 2024, we’re coming in with a pretty good set of contracts that we should be able to meet the target of 75 |
| The first is the added benefit to the patient of lower urinary tract symptom relief which improves their quality of life, and secondly, because in doing so there is no additional procedural complexity and minimal increase in ablation time |
| And I think if I look at history, I think our growth rate today is about 60%, and I think if we extrapolate, I think that the fact that the utilization per site is growing, the fact that new sites are coming on board, I don't have the ability to provide a decent guidance at this point, but I think I can tell you that our team is continues to be excited about the growth |
| We are thrilled that even at this early stage, when most patients are cash pay patients adoption continues to increase |
| The third pillar is to continue to innovate with the overall aim of increasing treatment efficacy, improving workflow efficiency, and expanding technology access to deliver an even better TULSA treatment experience for urologists and their patients |
| It is designed to demonstrate that the efficacy of the TULSA Procedure is not inferior to radical prostatectomy, while also demonstrating superior quality of life outcomes |
| That’s excellent at this point in the game |
| We are pleased to report that the rate of recruitment is continuing to increase with investigator experience and onboarding of additional sites |
| But yes, I think it’s a great question, and it is something that gives us more confidence about the future |
| We are also excited by increasing use of MR in the care continuum of prostate disease management |
| Fourth quarter 2023 revenue increased 60% from 1.3 million from the same period in 2022 |
| This retrospective analysis of 42 men with lesions abutting or involving the apical sphincter demonstrated promising safety and efficacy of TULSA in patients with extreme apical lesions, notably preserving pad-free urinary continents in all patients despite ablation near the external sphincter |
| Thereby, we have also begun work to build closer relationships with MR Companies to help maximize the tremendous opportunity for our technology that we see ahead |
| We believe that the success of this trial has the potential to gain TULSA's inclusion in the society guidelines, which is always a key driver for new technology adoption |
| In the fourth quarter, there were many poster and podium presentations featuring TULSA that continued to demonstrate the unique pixel by pixel precision of the technology, the flexibility to treat a variety of patients and customize the treatment plan to what is best for the patient, and the durability of efficacy and safety outcomes |
| For those of you who are shareholders, we appreciate your continued interest and support |
| We think that there is an economic model here that’s pretty compelling |
| There continues to be significant evidence from clinical trials as well as from commercially treated patients that we believe that TULSA is on its way to becoming one of the mainstream technologies for the treatment of prostate cancer |
| Specifically, the unique combination of urethral cooling and dual frequency capabilities which allows a higher ultrasound frequency with shorter wavelengths, enable tight margins and treatment right to the apical plane while limiting the amount of sound energy being absorbed in the external urinary sphincter |
| It is now routinely used in about 50% of patients being treated and physicians report increased confidence and shorter time in treatment |
| So I don't envision any issue there, and that, in fact, could be a – will be a positive in 2025, where I think that we'll see how it goes in the hospitals, where they're not necessarily big on cash pay patients, and they're – they might be wondering, well, gee, do I keep advertising or doing this, or do I wait another quarter or two, and so on |
| And so I think that is certainly one of the things we're looking and watching is how is that going to affect it, but I think generally speaking, we're feeling fairly comfortable with continuing to increase the top-line in 2024 |
| Statement |
|---|
| I think the negative side, because as you know, we're building a game-changing technology and there are always all kinds of different things that go on, and I think the negative side, I guess, is that majority of our patients today are cash pay patients |
| That actually was and has been an issue because we’re such a new technology that getting to routine pathways have been one of the things we’ve had to overcome |
| Overall, the company recorded a fourth quarter 2023 net loss of $8.9 million or $0.42 per common share, compared with a net loss of $9.5 million or $0.46 per common share for the same three month period in 2022 |
| I was just curious |
| So I think the bottom line, I don't envision that there will be a negative impact to the economics, whether it's radical prostatectomy or TULSA |
| But this is the best I can provide, that I do think that there won't be anything that will be negative as compared to radical prostatectomy |
| Patients with apical lesions are particularly challenging because of the proximity to the external urinary sphincter |
| I think that we – I think at least logically, as the reimbursement data unfolds, I think it’s possible that some of those commercial contracts or the corporate contracts could start to accelerate |
| Rick Wise So you're saying, are you – just to make sure I'm understanding your comment, so you're saying that hospitals might slow down as they wait for the code to be installed, and so the second half might be softer, or, I just want to make sure I'm understanding your intention there |
| So, I don't know how big that risk is |
Please consider a small donation if you think this website provides you with relevant information